Repozitorij Medicinskog fakulteta Sveučilišta u Zagrebu

Uloga epigenetski usmjerene terapije u liječenju difuznog B-velikostaničnog limfoma [Role of epigenetically oriented therapy in the diffuse large B-cell lymphoma]

Kalac, Matko (2010) Uloga epigenetski usmjerene terapije u liječenju difuznog B-velikostaničnog limfoma [Role of epigenetically oriented therapy in the diffuse large B-cell lymphoma]. PhD thesis, Sveučilište u Zagrebu.

[img]
Preview
PDF
Download (1560Kb) | Preview

    Croatian abstract

    Epigenetski orijentirana terapija potencijalno predstavlja novi način liječenja hematoloških novotvorina, uključujući i difuzni B-velikostanični limfom (DLBCL), pogotovo onih slučajeva koji su rezistentni na standardnu terapiju ili u bolesnika koji relapsiraju. U ovoj disertaciji pokazano je kako inhibitori histonske deacetilaze (HDACi) i hipometilirajuće tvari polučuju sinergistički učinak u zaustavljanju rasta malignih DLBCL stanica. Ovaj učinak je dokazan in vitro u analizi stanične vijabilnosti, indukcije apoptoze, aktivacije kaspaznog sustava te acetilacije histona računajući omjer relativnog rizika (RRR) u trajnim i primarnim limfomskim linijama. Učinkovitost panobinostata (LBH589) i decitabina u zaustavljanju rasta malignih stanica je potvrđena i u in vivo modelu ljudskog limfomskog ksenografta uz statistički značajnu razliku (p < 0.05) u prosječnom volumenu tumora na boku životinje u grupama koje su primile kombinaciju panobinostata i decitabina u odnosu na grupe životinja tretirane lijekom pojedinačno ili kontrolu koja je primila samo vektor. Mehanističko i molekularno objašnjenje sinergističkom učinku ove kombinacije istraženo je analizom metilacije genoma i promjene genske ekspresije tehnologijom mikropostroja kojima su identificirana tri potencijalna tumor supresora, TP73, MXD4 i CAV1, čija je aktivnost reaktivirana u limfomskim stanicama koje su tretirane panobinostatom i decitabinom. Spoznaje iz ove disertacije uključene su u širu analizu kako bi se stvorio model farmakologije i biologije sustava za B-stanične novotvorine, a praktično se primijenile u kliničkom istraživanju s epigenetski usmjerenom terapijom.

    English abstract

    Epigenetically targeted therapy potentially represents a novel way of treating hematologic malignancies, including diffuse large B-cell lymphoma (DLBCL), especially those cases resistant to standard therapeutic options and in patients with relapsed disease. As shown in this thesis, histone deacetylase inhibitors (HDACi) and hypomethylating agents yield synergistic effect in growth inhibition of malignant DLBCL cells. This effect has been demonstrated in in vitro analysis of cell viability, apoptosis induction, caspase system activation and histone acetylation in permanent and primary DLBCL lines utilizing the relative risk ration (RRR) calculations. Efficacy of decitabine and panobinostat (LBH589) in malignant cell growth inhibition has also been confirmed in in vivo human lymphoma xenograft model with a significant statistical difference (p < 0.05) in the mean tumour volume located on the flank of the animal in the group that received combination of decitabine and panobinostat compared to the single drug groups or the one that received vector only. Genome wide methylation analysis and gene expression profiling has been used to determine mechanistic and molecular basis for the synergistic effect of this combination. These analyses identified three potential tumour suppressors, TP73, MXD4 and CAV1, the synthesis of which was reactivated in cells treated with panobinostat and decitabine. Findings from this thesis are a part of a wider analysis in an effort to establish a pharmacology/biology systems model within B-cell neoplasm context. Practically, it will be a foundation for a clinical trial exploring efficacy of epigenetically targeted therapy.

    Item Type: Thesis (PhD)
    Mentor: Jakšić, Branimir
    Divisions: Izvan medicinskog fakulteta
    Depositing User: dr.med. Helena Markulin
    University: Sveučilište u Zagrebu
    Institution: Medicinski fakultet
    Number of Pages: 88
    Status: Unpublished
    Creators:
    CreatorsEmail
    Kalac, Matko
    Date: 10 May 2010
    Date Deposited: 06 Nov 2012 15:07
    Last Modified: 06 Nov 2012 15:07
    Subjects: WH Hemic and Lymphatic Systems > WH 120-540 Hematologic Diseases. Immunologic Factors. Blood Banks
    Related URLs:
      URI: http://medlib.mef.hr/id/eprint/1674

      Actions (login required)

      View Item

      Document Downloads

      More statistics for this item...